(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.

WESTON, Fla., April 14, 2026 /PRNewswire/ - Apotex Corp., in partnership with Orbicular Pharmaceutical Technologies Pvt. Ltd. and Gland Pharma Limited, today announced that the U.S. Food and Drug ...

BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Eli Lilly on Tuesday released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for ...

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection for pediatric patients weighing less than 60kg. The Food and Drug Administration (FDA) has approved a ...

The following reader question came in response to the column “Critical Guidance for Complying With Anesthesia Infection Control Rules,” which features insight from Clifford Gevirtz, MD, an ...

The approval expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care. Epinephrine is a non-selective alpha and beta adrenergic agonist.